BD Guides FY Adjusted EPS to $13.10-$13.30
BDX sits 61% above its 52-week low of $127.536 on elevated volume (2.6× avg).
Summary
BD issued full-year adjusted EPS guidance of $13.10 to $13.30, and for fiscal 2027 it sees revenue up low-single digits. The stock is trading near its 52-week high, so the bar is already elevated. This follows the Q3 update in August, when adjusted EPS topped estimates and full-year guidance was raised, and comes after the October announcement of a $19 billion U.S. manufacturing expansion tied to tariff relief. In the fourth quarter BD reported revenue of $5.27B, net income of $696M, EPS of $2.54 and adjusted EPS of $4.15, which beat the IBES estimate. The guidance range is the key number to square against consensus; the added revenue outlook gives it more to work with than the EPS range alone.
At the time of this announcement, BDX was trading at $205.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $57B. The 52-week trading range was $127.54 to $209.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.